Posted by Michael Wonder on 17 Jun 2021
Dupixent (dupilumab) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
17 June 2021 - The pre-filled pen offers an additional administration option for all Dupixent indications in patients aged 12 years and older.
Sanofi Canada announced today that a new 300 mg single-dose (single-use) pre-filled pen for Dupixent (dupilumab) is now available in Canada.
The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older with moderate-to-severe atopic dermatitis, severe asthma and severe chronic rhinosinusitis with nasal polyposis, for at-home administration.
